GeneDx Holdings Corp. (NASDAQ:WGS) Stock Position Lifted by EntryPoint Capital LLC

EntryPoint Capital LLC increased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 32.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,141 shares of the company's stock after buying an additional 2,953 shares during the period. GeneDx accounts for 0.4% of EntryPoint Capital LLC's holdings, making the stock its 6th largest position. EntryPoint Capital LLC's holdings in GeneDx were worth $933,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. William Blair Investment Management LLC bought a new stake in shares of GeneDx during the 4th quarter worth approximately $51,496,000. Fred Alger Management LLC acquired a new position in GeneDx during the third quarter valued at approximately $16,731,000. Zweig DiMenna Associates LLC bought a new stake in GeneDx during the fourth quarter worth $23,788,000. Raymond James Financial Inc. bought a new stake in GeneDx during the fourth quarter worth $20,371,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of GeneDx in the 3rd quarter valued at $7,533,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Trading Down 2.3 %

Shares of WGS stock traded down $2.14 during mid-day trading on Friday, reaching $92.20. 515,443 shares of the stock traded hands, compared to its average volume of 642,815. The stock's fifty day simple moving average is $87.28 and its two-hundred day simple moving average is $74.20. GeneDx Holdings Corp. has a 1-year low of $8.53 and a 1-year high of $115.60. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -47.04 and a beta of 1.91.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. On average, research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on WGS shares. The Goldman Sachs Group upped their price objective on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $72.33.

Insider Activity

In related news, CEO Katherine Stueland sold 51,420 shares of the business's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at $162,505.60. The trade was a 96.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kevin Feeley sold 402 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the transaction, the chief financial officer now owns 5,044 shares in the company, valued at approximately $454,212.20. The trade was a 7.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 183,032 shares of company stock worth $17,007,198 in the last quarter. 27.30% of the stock is owned by corporate insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.